Hepatitis C Virus Late Relapse after Sustained Virologic Response from Interferon and Ribavirin Treatment as Confirmed by RNA Sequencing

Journal of Clinical Microbiology

Volumn 52, Issue 1, 2014, Pages 367-369

  Lu, Yidan ^a   Andonov, Anton ^b   Wong, David K H ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; IMMUNOGLOBULIN; INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; CASE REPORT; DISEASE COURSE; DRUG DOSE REDUCTION; FEMALE; GENETIC DISTANCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; LIVER CIRRHOSIS; MIDDLE AGED; NEUTROPENIA; NONHUMAN; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; RNA SEQUENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD;

CLUSTER ANALYSIS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MIDDLE AGED; PHYLOGENY; RECURRENCE; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; SEQUENCE HOMOLOGY; VIRAL ENVELOPE PROTEINS; VIREMIA;

EID: 84891455002     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01367-13     Document Type: Article

References (14)

1. Formann E, Steindl-Munda P, Hofer H, Jessner W, Bergholz U, Gurguta C, Ferenci P. 2006. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment. Pharmacol. Ther. 23:507-511. http://dx.doi.org/10.1111/j.1365- 2036.2006.02785.x.
2. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, Giuily N, Castelnau C, Cardoso AC, Asselah T, Feray C, Nicolas-Chanoine MH, Bedossa P, Marcellin P. 2008. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 135:821-829. http://dx.doi.org/10.1053/j.gastro.2008 .05.044.
3. Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, Castillo I, Weiland O, Nevens F, Hansen BE, Schalm SW. 2004. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 53:1504-1508. http://dx.doi.org/10.1136/gut.2003.038257.
4. Desmond CP, Roberts SK, Dudley F, Mitchell J, Day C, Nguyen S, Pianko S. 2006. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J. Viral Hepat. 13:311-315. http://dx.doi.org/10.1111/j.1365-2893.2005. 00685.x.
5. Giannini EG, Basso M, Savarino V, Picciotto A. 2010. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment. Pharmacol. Ther. 31:502-508. http://dx.doi.org/10.1111/j.1365-2036.2009 .04201.x.
6. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessoa MG, Lin A, Tietz A, Connell EV, Diago M. 2010. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139: 1593-1601. http://dx.doi.org/10.1053/j.gastro.2010.07.009.
7. Welker MW, Zeuzem S. 2009. Occult hepatitis C: How convincing are the current data? Hepatology 49:665-675. http://dx.doi.org/10.1002/hep .22706.
8. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, Wilkinson J, Adair D, Rakela J, Laskus T. 2005. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 41:106-114. http://dx.doi.org/10.1002/hep.20518.
9. Veerapu NS, Raghuraman S, Liang TJ, Heller T, Rehermann B. 2011. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology 140:676-685.e1. http://dx.doi.org/10.1053/j.gastro.2010.10.048.
10. Lee WM, Polson JE, Carney DS, Sahin B, Gale M, Jr. 2005. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: Evidence for an occult viral reservoir. J. Infect. Dis. 192:1088-1092. http://dx.doi.org/10.1086/432917.
11. Fujii H, Itoh Y, Ohnishi N, Sakamoto M, Ohkawara T, Sawa Y, Nishida K, Nishimura T, Yamaguchi K, Yasui K, Minami M, Okanoue T, Ohkawara Y, Yoshikawa T. 2010. Relapse of hepatitis C in a pegylatedinterferon-alpha-2b plus ribavirin-treated sustained virological responder. Hepatol. Res. 40:654-660. http://dx.doi.org/10.1111/j.1872-034X.2010.00641.x.
12. Brjalin V, Salupere R, Tallo T, Kuznetsova T, Priimagi L, Tefanova V. 2012. Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C. Cent. Eur. J. Public Health 20:150-155.
13. Oze T, Hiramatsu N, Mita E, Akuta N, Sakamoto N, Nagano H, Itoh Y, Kaneko S, Izumi N, Nomura H, Hayashi N, Takehara T. 2013. A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Hepatol. Res. 43:35-43. http://dx.doi.org/10.1111/j.1872-034X.2012.01056.x.
14. Inglot M, Pawlowski T, Szymczak A, Malyszczak K, Zalewska M, Radkowski M. 2013. Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. Postepy. Hig. Med. Dosw. (Online) 67:186-191. http://dx.doi.org/10. 5604/17322693.1038785.